Abstract Expression of the receptor tyrosine kinase HER3 is negatively correlated with survival in ovarian cancer, and HER3 overexpression is associated with cancer progression and therapeutic resistance. Thus, improvements in HER3-targeted therapy could lead to significant clinical impact for ovarian cancer patients. Previous work from our group established multivalency as a potential strategy to improve the therapeutic efficacy of HER3-targeted ligands, including affibodies....
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Pulmonary complications post hematopoietic stem cell transplant in dyskeratosis congenita: analysis of oxidative stress in lung fibrobl...
-
Predictive Success Factors in Selective Upper Airway Stimulation. ORL J Otorhinolaryngol Relat Spec. 2017 Feb 24;79(1-2):121-128 Auth...
-
Background. Antitumor necrosis factor (anti-TNF) therapy is a highly effective but costly treatment for inflammatory bowel disease (IBD). Me...
-
Abstract Nonmotor symptoms (NMS) have been described in several neurodegenerative diseases but have not been systematically evaluated in sp...
-
Abstract Background The introduction of aggressive chemo-radiotherapy regimens has improved overall survival in children with primitive ...
-
Elementary school kids, on the other hand, can read, write, reason and think highly complex thoughts. Adele Faber and Elaine Mazlish, author...
-
by Mindaugas Paužuolis, Torsten Eich, Joachim Burman Background Natalizumab (NTZ) is a drug that has been widely used in the treatment of m...
-
by Jun Xu, Shuqing Chen, Baosheng Zeng, Anthony A. James, Anjiang Tan, Yongping Huang Manipulation of sex determination pathways in insect...
-
Abstract Purpose To develop the first photoactive biomaterial coating capable of controlled drug dosing via inclusion of synthesised drug-...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου